Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
San Francisco Examiner - January 18, 2007
Karl B. Hille, khille@baltimoreexaminer.com
"One of the big problems the institute has faced is we were straddling between two universities," institute director Dr. Robert Gallo said referring to the University of Maryland, Baltimore, and the University of Maryland Biotechnology Institute.
Previously residing in UMBI, the institute began 10 years ago as a partnership between the state, the city of Baltimore, the University System of Maryland and the University of Maryland Medical System, according to a release by IHV and the School of Medicine.
IHV's nearly 300 employees include more than 50 university faculty whose research focuses on chronic human viral infection and disease. More than 75 percent of the institute's clinical and research efforts target HIV, but viruses associated with hepatitis C, herpes and cancer are also in the virology institute's crosshairs.
However, fielding staff from both School of Medicine and UMBI made writing grants, cooperation and communication within the institute difficult.
Institute researchers have pulled more than 20 patents and discovered chemokines, the first known naturally occurring HIV inhibitors. Additionally, they created a genetic test for dangerous microbes that could lead to disease in the human body long before they can be detected by traditional means.
"The University of Maryland School of Medicine shares the entrepreneurial and scientific spirit embodied by the Institute of Human Virology," Dean E. Albert Reece said. "We are confident that IHV will contribute enormously to the many technologies and discoveries made by School of Medicine faculty in our search for treatments and cures for illnesses and diseases that affect people in Baltimore, Maryland and the world."
070118
SE070105
Copyright © 2007 - San Francisco Examiner. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Examiner, Permissions Desk, 110 Fifth Street, P.O. Box 7260, San Franciso, CA 94120.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .